Medexus Pharmaceuticals (TSX:MDP) Other Net Income (Loss) : C$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Other Net Income (Loss)?

Medexus Pharmaceuticals's Other Net Income (Loss) for the three months ended in Dec. 2023 was C$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.0 Mil.

Medexus Pharmaceuticals's quarterly Other Net Income (Loss) declined from Jun. 2023 (C$0.0 Mil) to Sep. 2023 (C$-0.0 Mil) but then increased from Sep. 2023 (C$-0.0 Mil) to Dec. 2023 (C$0.0 Mil).

Medexus Pharmaceuticals's annual Other Net Income (Loss) increased from Mar. 2021 (C$0.0 Mil) to Mar. 2022 (C$0.0 Mil) and increased from Mar. 2022 (C$0.0 Mil) to Mar. 2023 (C$0.0 Mil).

Medexus Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Medexus Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Other Net Income (Loss) Chart

Medexus Pharmaceuticals Annual Data

Trend

Dec13

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Net Income (Loss)

Get a 7-Day Free Trial

Medexus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Medexus Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.0 Mil.

Medexus Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals (TSX:MDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

MEDXF:USA P731:Germany

Address

35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1

Website

https://www.medexus.com

Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.

Executives

Benoit Gravel

Director